In a large and comprehensive cohort of persons in placebo-controlled trials of rFVIIa, treatment with high doses of rFVIIa on an off-label basis significantly increased the risk of arterial but not venous thromboembolic events, especially among the elderly. (Funded by Novo Nordisk.).

No abstract

No abstract

Patients with MDD responded well to long-term treatment with either escitalopram or citalopram. This study demonstrated the importance of extending treatment of depression beyond 8 weeks.

Background: Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and delaying disease worsening is a relevant treatment outcome. Methods: Data from 6 randomized, double-blind, placebo-controlled, 6-month studies were pooled and a subgroup of patients (867 on placebo, 959 on memantine) with moderate to severe AD (Mini- Mental State Examination <20) was analyzed. ‘Any clinical worsening’ was defined as a decline on the Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog) or the Severe Impairment Battery (SIB) and on the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-plus) and the Alzheimer’s Disease Cooperative Study – Activities of Daily Living Inventory (ADCS-ADL), and ‘marked clinical worsening’ as ≧4 points decline on the ADAS-cog or ≧5 points on the SIB and decline on the CIBIC-plus and the ADCS-ADL. Results: More placebo-treated than memantine-treated patients showed any clinical worsening (28 vs. 18%; p < 0.001), and 21% placebo-treated patients compared to 11% memantine-treated patients had marked clinical worsening (p < 0.001). Conclusion: In this population of moderate and severe AD patients, treatment with memantine was associated with reducing worsening of clinical symptoms in AD during the 6-month study period.